LAYN Serves as a Prognostic Biomarker and Downregulates Tumor-Infiltrating CD8+ T Cell Function in Hepatocellular Carcinoma
DOI: https://doi.org/10.2147/jhc.s464806
2024-06-07
Journal of Hepatocellular Carcinoma
Abstract:Shuxiu Xiao, 1, &ast Lili Lu, 1, &ast Zhiyuan Lin, 2, &ast Xinming Ye, 3 Sheng Su, 3 Chenlu Zhang, 4 Yang You, 4 Wei Li, 4 Xiaowu Huang, 3 Weizhong Wu, 5 Yuhong Zhou 1, 4 1 Clinical Center for Biotherapy, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China; 2 Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China; 3 Department of Liver Surgery and Transplantation, and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China; 4 Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China; 5 Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, 200032, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yuhong Zhou; Weizhong Wu, Email ; Background: Layilin (LAYN) represents a valuable prognostic biomarker across various tumor types, while also serving as an innovative indicator of dysfunctional or exhausted CD8 + T cells and exhibiting correlation with immune context. However, the immune function and prognostic significance of LAYN in hepatocellular carcinoma (HCC) remain unexplored. Therefore, our objective is to investigate the role of LAYN in CD8 + T cell exhaustion, clinical prognosis, and the tumor microenvironment within HCC. Methods: TIMER or GEPIA databases were used to analyze LAYN expression level and its correlation with immune infiltration in HCC. Bioinformatics analysis was conducted on TCGA and scRNA-seq cohorts. The evaluation of LAYN expression level in fresh specimens was performed through IF, IHC, and ELISA assays. Flow cytometry and mRNA-seq were employed to investigate co-expressed genes of LAYN, the LAYN + CD8 + T cell exhaustion signature and immune function. Cell proliferation ability and killing activity were assessed using CCK8 and CFSE/PI. Results: The expression level of LAYN in HCC tumors was significantly higher compared to peri-tumors. Patients with high levels of LAYN exhibited poorer OS. GO or KEGG analysis confirmed that LAYN was involved in immune response and was positively associated with CD8 + T cell immune infiltration levels. Furthermore, LAYN negatively regulated the immune function of CD8 + T cells, leading to dysfunctional phenotypes characterized by elevated levels of CD39, TIM3 and reduced levels of perforin, TNF-α, Ki-67. CFSE/PI assays demonstrated that LAYN + CD8 + T cells displayed decreased cytotoxic activity. Additionally, there was a positive correlation between LAYN and CD146 levels, which are involved in adhesion and localization processes of CD8 + T cells. Interestingly, blocking LAYN partially restored the exhaustion properties of CD8 + T cells. Conclusion: LAYN exhibits a strong correlation with immune infiltration in the TME and represents a novel biomarker for predicting clinical prognosis in HCC. Moreover, targeting LAYN may hold promise as an effective strategy for HCC immunotherapy. Keywords: hepatocellular carcinoma, layilin, CD8 + T cell exhaustion, prognosis Graphical Liver cancer is currently one of the cancers with high incidence rates, ranking as the fifth most malignant cancer in China and having the second highest mortality rate (0.91) worldwide. 1,2 Annually, there are approximately 854,000 new cases and 695,000 deaths, with 85–90% of them being individuals diagnosed with HCCs. 3 Malignancy typically develops in patients suffering from chronic liver disease caused by hepatitis B virus (HBV) or hepatitis C virus (HCV) infection or metabolic diseases. 4,5 Until recently, treatment options for HCC include liver transplantation, surgical resection, and molecular targeted therapy. 6 Unfortunately, available therapeutic approaches for HCC were limited and ineffective resulting in a recurrence and metastasis rate of 70% within five years. 3 Cancer immunotherapy has significantly revolutionized the prospects for oncology treatment in the past decade. 7 The recent success of immune checkpoint inhibitors (ICIs) like pembrolizumab and nivolumab, which obstruct the programmed cell death 1 (PD1)-PD-L1 pathway, has stimulated research on immune therapy in HCC. 8 -Abstract Truncated-
oncology